What is happening at Pivot Park?



Category: News

Symeres acquires Oncolines, further strengthening its drug discovery and biology capabilities

Symeres, a leading global drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), announces the acquisition of Oncolines, a Netherlands-based CRO that provides early biology services and cell-line profiling assays. Oncolines is Symeres’ third acquisition in the past ten months, and will take group revenues to over €100m.

Read More »

10 years Pivot Park: Pivot Park

Pivot Park has become an essential location for biopharmaceutical innovation and drug discovery in Europe. The latest addition to Pivot Park is an eight-floor multitenant office and lab space, and the shell of the next building is already up. This additional accommodation is a testament to the steady, continuous growth of Pivot Park.

Read More »

10 years Pivot Park: Nelisca

“It was a revelation for me. As Accountants, we usually look back at the end of every year. But to work with partners in Life Science we needed a change of mind set. We wanted to collaborate and facilitate more, to help our clients achieve their goals. We think along with our clients and help them build healthy, growing companies.”

Read More »

Donation Voedselbank Oss

Yesterday we donated a total amount of 2000 euros to Voedselbank Oss while we visited them. The words “grateful” and “more than welcome” came to the table.

Read More »

10 years Pivot Park: 3D-PharmXchange

François van Och, one of the three managing partners, explains: “By offering independent strategic project management, you are a credible advocate for clients and their projects. This creates synergy between the disciplines and intensive collaboration with the parties we work for. And that’s important for an effective time and cost-efficient process.”

Read More »

10 years Pivot Park: Innatoss

Innatoss is a diagnostic laboratory specialising in infectious diseases such as Lyme disease, Q fever and since 2020, COVID-19. Innatoss is pushing the boundaries of diagnostics by making innovative use of existing tests. If no such tests exist then Innatoss will develop them. The laboratory regularly supports and assists leading organisations in addressing infectious diseases in the work place.

Read More »
Surviving the Dutch participants with their certificate

Surviving the Dutch graduation

Yesterday a group of international community members finished the second edition of the ‘Surviving the Dutch Program’ at Pivot Park. For 10 weeks they have taken Dutch lessons followed by either Dutch culture training or group activities.

Read More »

10 years Pivot Park: BioConnection

BioConnection’s operational expertise is filling vials and syringes for small to medium-sized pharmaceutical companies and Bio-techs. In 17 years since it was founded, this Contract Development and Manufacturing Organisation (CDMO) has grown into a major company with a global customer base.

Read More »

10 years Pivot Park: Oncolines

“Oncolines is a subsidiary of the Netherlands Translational Research Center (NTRC), the company I started in 2012 with my MSD/Organon colleague Rogier Buijsman,” says Zaman. “From 2012 to 2021, NTRC worked on new technologies to help develop novel drug candidates. These include a cancer cell line panel and bioinformatics analysis tools. We used these technologies to support our in-house drug discovery but also to provide services for clients. Over the years, NTRC has developed so fast that we decided to separate the precision medicine services and to expand it further as Oncolines.”

Read More »

Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards

Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of November at the Old Billingsgate in London, UK.

Read More »

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?


The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.